Parexel Acquires Vitrana to Expand AI-Enabled Pharmacovigilance Capabilities
Summary (EN)
Digital Health News reported on May 2 that Parexel has acquired Vitrana, an AI-enabled pharmacovigilance technology provider, to expand its patient-safety operations and combine safety services and technology in one model. Vitrana’s platform is described as system-agnostic, meaning it can integrate with existing safety databases rather than forcing sponsors to replace their current infrastructure. The acquisition is intended to support end-to-end pharmacovigilance workflows, including electronic data capture integration, serious adverse event reconciliation, and digital adverse-event reporting from patients. The combined offering is positioned as a move away from fragmented vendor arrangements toward a single provider that can manage both the technology layer and operational service delivery. The article says this could reduce duplicate data entry for clinical trial sites, improve connectivity between EDC systems and safety databases, and speed reconciliation of safety cases. For sponsors, the integrated model is meant to simplify oversight and compliance across global clinical development programs. Parexel leadership framed the deal as a way to improve efficiency and maintain first-time quality in safety reporting, while Vitrana leadership said Parexel’s global infrastructure would enable broader deployment of its technology. Vitrana will initially operate as “Vitrana – a Parexel Company” while being integrated into Parexel’s Patient Safety Services organization. Both publication and reported acquisition timing fall within the past 24 hours.
Summary (ZH)
Digital Health News 5 月 2 日报道，临床研究组织 Parexel 已收购 AI 药物警戒技术提供商 Vitrana，以扩展其患者安全运营能力，并把安全服务与技术平台整合到同一模式中。Vitrana 的平台被描述为“系统无关”，可与现有安全数据库集成，而不是要求申办方替换既有基础设施。此次收购旨在支持端到端药物警戒流程，包括电子数据采集（EDC）集成、严重不良事件（SAE）核对，以及患者端数字化不良事件报告。报道称，合并后的方案意在从碎片化供应商模式转向单一提供方模式，由同一体系同时承担技术层和运营服务交付。对临床试验中心而言，这可能减少重复录入，改善 EDC 系统与安全数据库之间的连接，并加快安全病例核对。对申办方而言，整合模型有助于简化全球临床开发项目中的药物警戒监督和合规要求。Parexel 管理层表示，这笔交易将提升运营效率并支持安全报告的一次性质量；Vitrana 管理层则称 Parexel 的全球基础设施将帮助其技术在国际市场更广泛部署。Vitrana 初期将以 “Vitrana – a Parexel Company” 名义运营，并逐步并入 Parexel Patient Safety Services 组织。报道和交易披露均在过去 24 小时内。
Source